CL2009001214A1 - Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos - Google Patents
Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicosInfo
- Publication number
- CL2009001214A1 CL2009001214A1 CL2009001214A CL2009001214A CL2009001214A1 CL 2009001214 A1 CL2009001214 A1 CL 2009001214A1 CL 2009001214 A CL2009001214 A CL 2009001214A CL 2009001214 A CL2009001214 A CL 2009001214A CL 2009001214 A1 CL2009001214 A1 CL 2009001214A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutical composition
- modulators
- serine proteases
- thromboembolic disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Compuestos heterocíclicos moduladores de la serina proteasa, composición farmacéutica, útil para el tratamiento de un trastorno mediado por el factor ixa, donde dicho trastorno es un trastorno tromboembólico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5431008P | 2008-05-19 | 2008-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009001214A1 true CL2009001214A1 (es) | 2010-12-31 |
Family
ID=41066042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009001214A CL2009001214A1 (es) | 2008-05-19 | 2009-05-18 | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos |
Country Status (11)
Country | Link |
---|---|
US (1) | US8148363B2 (es) |
EP (2) | EP2300435A2 (es) |
JP (1) | JP5504259B2 (es) |
CN (1) | CN102099340A (es) |
AR (1) | AR071823A1 (es) |
CA (1) | CA2724430A1 (es) |
CL (1) | CL2009001214A1 (es) |
MX (1) | MX2010012635A (es) |
PE (1) | PE20091972A1 (es) |
TW (1) | TW201008930A (es) |
WO (1) | WO2009143039A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG176105A1 (en) * | 2009-06-26 | 2011-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
CN103119036B (zh) * | 2010-06-28 | 2018-05-08 | 拜耳知识产权有限责任公司 | 作为杀虫剂的杂环化合物 |
UY33476A (es) | 2010-06-30 | 2012-02-29 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
RU2582679C2 (ru) | 2010-11-09 | 2016-04-27 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
MX359399B (es) | 2011-04-28 | 2018-09-27 | Novartis Ag | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. |
WO2013009527A2 (en) | 2011-07-08 | 2013-01-17 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
CN106117194A (zh) | 2011-12-27 | 2016-11-16 | 铁木医药有限公司 | 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类 |
CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
EP2934537B1 (en) * | 2012-12-19 | 2018-04-04 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
US9695198B2 (en) | 2012-12-19 | 2017-07-04 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
CN105209440B (zh) | 2013-03-15 | 2019-07-23 | 维颂公司 | 作为凝血酶抑制剂的卤代吡唑 |
LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
WO2015160636A1 (en) | 2014-04-16 | 2015-10-22 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
KR102496364B1 (ko) * | 2014-09-10 | 2023-02-06 | 에피자임, 인코포레이티드 | Smyd 억제제 |
WO2016044645A1 (en) * | 2014-09-17 | 2016-03-24 | Elmaleh David R | Anticoagulant derivatives for cardiovascular imaging |
CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
SI3226858T1 (sl) * | 2014-12-04 | 2021-07-30 | Procomcure Biotech Gmbh | Protimikrobna sredstva na osnovi imidazola |
US10314820B2 (en) | 2014-12-04 | 2019-06-11 | Procomcure Biotech Gmbh | Imidazole-based heterocyclic compounds |
WO2016133793A1 (en) * | 2015-02-16 | 2016-08-25 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
CA2977993A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
AU2017247806B2 (en) * | 2016-04-07 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
CA3019630A1 (en) * | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
US11014920B2 (en) | 2016-11-18 | 2021-05-25 | Merck Sharp & Dohme Corp. | Factor XIIa inhibitors |
WO2019204447A1 (en) * | 2018-04-17 | 2019-10-24 | The Regents Of The University Of Michigan | Inhibitors of platelet function and methods for use of the same |
CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
PL203771B1 (pl) | 1998-07-06 | 2009-11-30 | Bristol Myers Squibb Co | Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
SK287026B6 (sk) | 2000-06-15 | 2009-10-07 | Schering Corporation | Nor-seko-himbacínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
US7037920B2 (en) | 2001-10-18 | 2006-05-02 | Schering Corporation | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists |
IL161576A0 (en) * | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
EP1982984B1 (en) | 2002-04-16 | 2013-02-13 | Merck Sharp & Dohme Corp. | Manufacture of tricyclic thrombin receptor antagonists and pharmaceutical compositions comprising them |
JP2007506741A (ja) * | 2003-09-23 | 2007-03-22 | メルク エンド カムパニー インコーポレーテッド | 向代謝性グルタミン酸受容体のピラゾール系調節剤 |
CA2572745A1 (en) * | 2004-07-07 | 2006-02-16 | Teresa Beeson | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
EP1773330B1 (en) * | 2004-07-22 | 2010-05-26 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
US8710038B2 (en) * | 2004-09-17 | 2014-04-29 | Exelixis, Inc. | Pyrazole kinase modulators and methods of use |
JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
US8623818B2 (en) * | 2008-05-16 | 2014-01-07 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
-
2009
- 2009-05-18 EP EP09751268A patent/EP2300435A2/en not_active Ceased
- 2009-05-18 MX MX2010012635A patent/MX2010012635A/es active IP Right Grant
- 2009-05-18 WO PCT/US2009/044291 patent/WO2009143039A2/en active Application Filing
- 2009-05-18 US US12/993,607 patent/US8148363B2/en active Active
- 2009-05-18 EP EP14173412.9A patent/EP2805939B1/en active Active
- 2009-05-18 CA CA2724430A patent/CA2724430A1/en not_active Abandoned
- 2009-05-18 CN CN200980128238XA patent/CN102099340A/zh active Pending
- 2009-05-18 JP JP2011510610A patent/JP5504259B2/ja not_active Expired - Fee Related
- 2009-05-18 TW TW098116429A patent/TW201008930A/zh unknown
- 2009-05-18 AR ARP090101778A patent/AR071823A1/es not_active Application Discontinuation
- 2009-05-18 PE PE2009000694A patent/PE20091972A1/es not_active Application Discontinuation
- 2009-05-18 CL CL2009001214A patent/CL2009001214A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009143039A3 (en) | 2010-07-08 |
JP5504259B2 (ja) | 2014-05-28 |
EP2300435A2 (en) | 2011-03-30 |
WO2009143039A2 (en) | 2009-11-26 |
EP2805939B1 (en) | 2018-06-27 |
PE20091972A1 (es) | 2010-01-15 |
CN102099340A (zh) | 2011-06-15 |
TW201008930A (en) | 2010-03-01 |
US8148363B2 (en) | 2012-04-03 |
CA2724430A1 (en) | 2009-11-26 |
US20110065682A1 (en) | 2011-03-17 |
MX2010012635A (es) | 2010-12-06 |
JP2011520967A (ja) | 2011-07-21 |
EP2805939A1 (en) | 2014-11-26 |
AR071823A1 (es) | 2010-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009001214A1 (es) | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos | |
CL2007001674A1 (es) | Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas. | |
AR070497A1 (es) | Composicion detergente que comprende lipasa | |
AR055428A1 (es) | Escision de precursores de insulinas mediante una variante de tripsina | |
UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
CO6501153A2 (es) | Inhibidores macrociclicos de serina proteasa | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CR9869A (es) | Compuestos activos en ppar | |
SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
CR20140087A (es) | Anticuerpos a pcsk9 y usos de los mismos | |
CL2007001391A1 (es) | Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico | |
CL2009000316A1 (es) | Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos. | |
CO6390069A2 (es) | Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog. | |
NO20061122L (no) | 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer | |
NI200900093A (es) | Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
ECSP088864A (es) | Moduladores i mglur5 | |
EA201000070A1 (ru) | Модуляторы калликреина 7 | |
ECSP077269A (es) | Ácidos de oxazolo - naftilo como moduladores del ácidos de oxazolo - naftilo como moduladores del inhibidor del activador de plasminógeno tipo 1 (pai-1) | |
BR112012019042A8 (pt) | compostos inibidores de serina protease tipo tripsina, seu uso, e seus processos de preparação |